Literature DB >> 32523272

Gastrectomy with D2 Lymphadenectomy for Carcinoma of the Stomach in a Stand-alone Cancer Centre in Rural India.

Nizamudheen Mangalasseri Pareekutty1, Sachin Kadam2, Basavaraj Ankalkoti1, Satheesan Balasubramanian1, Bindu Anilkumar3.   

Abstract

CONTEXT: The therapeutic role of D2 lymphadenectomy in the management of gastric cancer is an ongoing controversy. AIMS: To examine the morbidity and oncological outcomes of D2 lymph node dissection for gastric cancer patients treated in a stand-alone cancer center in rural India and to compare it with international data. SETTINGS AND
DESIGN: Retrospective study on patients treated for gastric cancer from June 2009 to December 2014. METHODS AND MATERIAL: All patients underwent subtotal or total gastrectomy with modified D2 lymph node dissection preserving spleen and pancreas. The Clavien-Dindo model was used to stratify the severity of morbidity. STATISTICAL ANALYSIS: Descriptive statistics was used for data exploration. Chi-square test was used to compare the association of various factors with survival. Kaplan-Meier method was used to calculate the survival rates (RFS and DFS). Log-rank test was used to compare the survival of different subgroups.
RESULTS: Fifty-four patients (41 males and 13 females) were included in the study. Four (7.4%) patients had significant postoperative morbidity. The 5-year OS and DFS respectively were 34.9% and 37.6%. Female sex was associated with poorer survival. Lymph node ratio of more than 0.2 and advanced stage at presentation showed strong tendency towards lower OS and DFS.
CONCLUSIONS: An R0 resection with D2 lymphadenectomy for gastric cancer carries acceptable morbidity and mortality in Indian patients with survival rates comparable with the western studies. Lymph node ratio more than 0.2 and female gender and advanced stage were associated with poorer oncological outcomes. © Indian Association of Surgical Oncology 2020.

Entities:  

Keywords:  D2 lymphadenectomy; Gastrectomy; Lymph node ratio; Stomach cancer

Year:  2020        PMID: 32523272      PMCID: PMC7260343          DOI: 10.1007/s13193-020-01059-w

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  24 in total

1.  Does lymph node ratio affect prognosis in gastroesophageal cancer?

Authors:  Marcovalerio Melis; Antonio Masi; Antonio Pinna; Steven Cohen; Ioannis Hatzaras; Russell Berman; Leon H Pachter; Elliot Newman
Journal:  Am J Surg       Date:  2015-04-24       Impact factor: 2.565

2.  Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study.

Authors:  Franco Roviello; Daniele Marrelli; Paolo Morgagni; Giovanni de Manzoni; Alberto Di Leo; Carla Vindigni; Luca Saragoni; Anna Tomezzoli; Hayato Kurihara
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

3.  Evaluation of prognostic value and stage migration effect using positive lymph node ratio in gastric cancer.

Authors:  S Komatsu; D Ichikawa; M Nishimura; T Kosuga; K Okamoto; H Konishi; A Shiozaki; H Fujiwara; E Otsuji
Journal:  Eur J Surg Oncol       Date:  2016-08-21       Impact factor: 4.424

4.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

5.  Predictors of operative morbidity and mortality in gastric cancer surgery.

Authors:  D J Park; H-J Lee; H-H Kim; H-K Yang; K U Lee; K J Choe
Journal:  Br J Surg       Date:  2005-09       Impact factor: 6.939

6.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

Authors:  Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia
Journal:  Lancet Oncol       Date:  2013-12-05       Impact factor: 41.316

7.  Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer.

Authors:  C W Wu; C A Hsiung; S S Lo; M C Hsieh; L T Shia; J Whang-Peng
Journal:  Br J Surg       Date:  2004-03       Impact factor: 6.939

8.  Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer.

Authors:  A M Bunt; J Hermans; M C Boon; C J van de Velde; M Sasako; G J Fleuren; J A Bruijn
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

9.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

10.  Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomes.

Authors:  Povilas Kavaliauskas; Rytis Maziukas; Narimantas Evaldas Samalavicius; Justas Kuliavas; Raimundas Lunevicius
Journal:  Ann Med Surg (Lond)       Date:  2016-01-20
View more
  1 in total

Review 1.  Progress of Gastric Cancer Surgery in the era of Precision Medicine.

Authors:  Yumin Wang; Luyuan Zhang; Yi Yang; Shan Lu; Hao Chen
Journal:  Int J Biol Sci       Date:  2021-03-02       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.